Todd Kinsella
Corporate Officer/Principal at Vividion Therapeutics, Inc.
Profile
Todd Kinsella is currently the Head-Biology at Vividion Therapeutics, Inc. He previously worked as Vice President-Research at Rigel Pharmaceuticals, Inc. Dr. Kinsella holds a doctorate degree from Stanford University and an undergraduate degree from the University of Arizona.
Todd Kinsella active positions
| Companies | Position | Start |
|---|---|---|
Vividion Therapeutics, Inc.
 Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 2017-11-30 |
Former positions of Todd Kinsella
| Companies | Position | End |
|---|---|---|
| RIGEL PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
Training of Todd Kinsella
| University of Arizona | Undergraduate Degree |
| Stanford University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| RIGEL PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Commercial Services |
- Stock Market
- Insiders
- Todd Kinsella
